Table 2.

Patients' characteristics according to invasive front CD3, invasive front CD8, and immune cell PD‐L1 expressions in chemo‐naive patients with metastases.

Parameter	Invasive front CD3 in metastases			Invasive front CD8 and immune cells PD‐L1 in metastases
	CD3 high	CD3 low	P	CD8high PD‐L1 high	CD8 low PD‐L1 high	CD8 low PD‐L1 low	P
Age (years)
N	31	3		7	16	10
Median (range)	61 (45–75)	68 (66–74)	0.089	64.2 (45–75)	59.6 (50–71)	64.6 (53–75)	0.332
Longest diameter of metastases (cm), N (%)
N	30	3		7	16	9
≤ 5	29 (96.7)	2 (66.7)	0.176	7 (100.0)	16 (100.0)	7 (77.8)	0.115
> 5	1 (3.3)	1 (33.3)		0 (0.0)	0 (0.0)	2 (22.2)
N‐stage, N (%)
N	30	3		7	16	9
N0	17 (56.7)	1 (33.3)	0.579	4 (57.1)	11 (68.8)	3 (33.3)	0.247
N+	13 (43.3)	2 (66.7)		3 (42.9)	5 (31.3)	6 (66.7)
Number of metastases, N (%)
N	30	3		7	16	9
Mean (SD)	1.4 (0.77)	3.3 (3.21)	0.153	1.1 (0.38)	1.6 (0.73)	2.1 (2.09)	0.408
≤ 1	21 (70.0)	1 (33.3)	0.252	6 (85.7)	9 (56.3)	6 (66.7)	0.439
> 1	9 (30.0)	2 (66.7)		1 (14.3)	7 (43.8)	3 (33.3)
Preoperative CEA level (ng·mL−1)
N	28	3		7	16	8
Mean (SD)	28.0 (64.22)	6.3 (7.33)	0.640	7.5 (5.17)	13.9 (34.10)	66.0 (105.31)	0.052
Timing of metastases, N (%)
N	31	3		7	16	10
Metachronous	11 (35.5)	1 (33.3)	1.000	2 (28.6)	7 (43.8)	3 (30.0)	0.715
Synchronous	20 (64.5)	2 (66.7)		5 (71.4)	9 (56.3)	7 (70.0)
Sex, N (%)
N	31	3		7	16	10
Male	18 (58.1)	3 (100.0)	0.270	6 (85.7)	7 (43.8)	8 (80.0)	0.081
Female	13 (41.9)	0 (0.0)		1 (14.3)	9 (56.3)	2 (20.0)
Tumor sidedness, N (%)
N	30	3		7	16	10
Right‐sided	6 (20.0)	1 (33.3)	0.524	1 (14.3)	3 (18.8)	3 (30.0)	0.742
Left‐sided (with rectum)	24 (80.0)	2 (66.7)		6 (85.7)	13 (81.3)	7 (70.0)